MarketPulse

clinical risk

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Iovance's Cell Therapy Bet: $1B Revenue Dream Amid Manufacturing Headwinds

Iovance's Amtagvi cancer therapy targets $1B+ revenue by 2030 amid strong early growth, but faces manufacturing cost and regulatory risks.
IOVAbiotechoncology
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics Advances Weight-Loss Candidate Into Late-Stage Trials

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.
LLYNVOVKTXbiotechweight loss drugs